Abstract:A panel of experts recently completed updating the European Guidelines for the use of Ultrasound Contrast Agents. It is due to be published in early 2008 and updates and extends the 2004 Guidelines, which covered only the liver. The new liver section, which includes the use of USCM in interstitial ablation, incorporates the recent Barcelona guidelines for management of focal lesions discovered during ultrasound surveillance in cirrhotic patients. Though focussed on SonoVue, it forms a useful framework for a general discussion of this topic. It also covers clinically established uses in the kidneys and pancreas, in abdominal trauma, in vesico-ureteric reflux and in transcranial studies. The liver section of the guidelines opens with a rationale for beginning with characterisation of focal lesions rather than their detection, as may seem logical. This points up a fundamental awkwardness of the way USCM work in the liver: the initial arterial phase is particularly useful for differentiating between various focal lesions, while the late (sinusoidal) phase is critical for determining the malignant nature of solid liver lesions. Benign lesions such as haemangiomas and focal nodular hyperplasia have a rich arterial supply and often enhance early in the arterial phase. In haemangiomas, the blood enters the lakes that constitute the abnormality at the periphery of the lesion, giving rise to peripheral nodular enhancement. From here, it percolates towards the centre of the haemangioma, usually fairly slowly, taking up to five minutes to fill completely. At this stage, the lesion disappears as it matches the intensity of the enhanced liver parenchyma, though the process is incomplete in haemangiomas that contain thrombus, usually larger lesions. Thus, delayed scanning is required to confirm that the lesion has disappeared or at least become smaller. FNHs also have an arterial supply via one or several tortuous feeding vessels. However, the flow pattern is distinctive, arriving first at the centre of the lesion and filing it in a centrifugal fashion, often forming a spoke wheel pattern. The enhancement is often intense and very rapid (the “light bulb sign”) and so the early images after arrival of the contrast are critical; the study should be recorded so that these early frames can be reviewed, if necessary in slow motion, to allow the characteristic pattern to be recognised. In the late phase, FNHs disappear as the liver enhancement matches the enhancement in the lesion. In around a quarter of cases, the central scar becomes visible in this phase as a stellate central filling defect. For both lesions, these features carry the same confidence as the equivalent CT or MR haemodynamic findings and do not require further investigation when they are typical, as is the case in around 75% of cases. Atypical cases, which amount to 5 or 10%, require further investigation. Other lesions with diagnostic haemodynamic patterns are focal fatty sparing and change as well as regenerating nodules: they have normal haemodynamics and so behave in exactly the same way as the surrounding liver, disappearing in the late phase. Hepatic adenomas seem to have a variety of patterns, but experience with them is still limited, as it is for other uncommon focal lesions such as granulomas and peliosis.

Optimal MR Protocol for Hepatic Hemangiomas

Study of Clinical Application of Hepatic-Biliary Specific MR Contrast Agent(gd-Eob-dtpa) in the Diagnosis of Focal Hepatic Lesions

Clinical Evaluation of 3.0T Dynamic Contrast Enhanced MRI in Liver Lesion

A comparative study of contrast enhanced ultrasound and contrast enhanced magnetic resonance imaging for the detection and characterization of hepatic hemangiomas.

Optimal pulse sequence for ferumoxides-enhanced MR imaging used in the detection of hepatocellular carcinoma: a comparative study using seven pulse sequences

Dynamic MRI and Diffusion Weighted Imaging for Small Atypical Hepatic Hemangiomas

The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence

MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio

Multiarterial phase dynamic contrast-enhanced 3D MR imaging of the whole liver in 3.0T MR: preliminary study

- 32S 2-1 9 th US Contrast The Diagnosis of Liver Tumours with Ultrasound Contrast

Diagnostic value and characterization of contrast enhanced ultrasound for hepatic giant hemangionmas

The differential enhancement pattern of contrast enhanced ultrasound and magnetic resonance imaging characteristics in hepatic angiomyolipoma: 7 case reports

Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions

Breath-hold High-resolution T1-weighted Gradient Echo Liver MR Imaging with Compressed Sensing Obtained during the Gadoxetic Acid-enhanced Hepatobiliary Phase: Image Quality and Lesion Visibility Compared with a Standard T1-weighted Sequence

Study of Diagnostic Values of Dynamic MRI and Diffusion Weighted Imaging in Small Hepatic Hemangiomas(≤2 cm)

Detection of small hepatocellular carcinoma: comparison of conventional gadolinium-enhanced MRI with gadolinium-enhanced MRI after the administration of ferucarbotran

Differential Diagnosis of Hemangiomas from Spinal Osteolytic Metastases Using 3.0 T MRI: Comparison of T1-weighted Imaging, Chemical-Shift Imaging, Diffusion-Weighted and Contrast-Enhanced Imaging

Characteristics of Parametric Imaging of Contrast-Enhanced Ultrasound for Hepatic Hemangioma

Comparison of Gadoxetate Disodium and Gadopentetate Dimeglumine in Dynamic Contrast-Enhanced Liver MRI:an Intra-Individual Comparative Study

Enhancement Patterns of Small Hepatocellular Carcinoma Shown by Dynamic MRI and CT.

Role and Pitfalls of Hepatic Helical Multi-Phase CT Scanning in Differential Diagnosis of Small Hemangioma and Small Hepatocellular Carcinoma.